免疫检查点抑制剂相关心肌炎的诊治进展

Progress in diagnosis and treatment of immune checkpoint inhibitors-associated myocarditis

免疫调节是控制恶性肿瘤进展的重要决定因素,免疫检查点抑制剂(ICIs)的应用为恶性肿瘤治疗带来突破性进展,很大程度上改善了患者的生存时间和生活质量,然而不可避免的是,其也带来免疫相关不良反应(irAE)毒性风险。本文就ICIs相关心肌炎的发病机制、发病率、诊断和治疗策略进行综述。

Immune regulation is an important determinant for the control of the malignant tumors progression.The application of immune checkpoint inhibitors(ICIs)has brought breakthroughs in the treatment of malignant tumors,and greatly improve the survival time and quality of life of patients.However,it is inevitable that the ICIs also brings the toxicity risk of immune-related adverse events(irAE).This paper reviews the mechanism,incidence,diagnosis and treatment strategies of ICIs-associated myocarditis.